ECT2的上调预示胃癌患者不良临床结局并增加5-氟尿嘧啶耐药性。
Upregulation of ECT2 Predicts Adverse Clinical Outcomes and Increases 5-Fluorouracil Resistance in Gastric Cancer Patients.
作者信息
Zhang Hua, Geng Yuan, Sun Chunhui, Yu Jin
机构信息
Department of Pharmacy, Yantaishan Hospital, Yantai 264000, Shandong, China.
Department of Obstetrics, Medical Insurance Office, Qingdao Municipal Hospital, Qingdao 266000, Shandong, China.
出版信息
J Oncol. 2021 Jul 28;2021:2102890. doi: 10.1155/2021/2102890. eCollection 2021.
BACKGROUND
The abnormal expression and prognosis prediction of epithelial cell transforming sequence 2 (ECT2) in gastric cancer (GC) has been reported. However, the effect of ECT2 on 5-fluorouracil (5-Fu) resistance in GC is unclear. This research aims to solve the abovementioned problems.
METHODS
Gene expression was detected by RT-qPCR and Western blot analysis. Cell viability was evaluated by the colony formation assay, MTT assay, and flow cytometric analysis. Transwell and wound healing assays were used to detect cell metastasis.
RESULTS
Upregulation of ECT2 was found in stomach adenocarcinoma (STAD) and GC tissues. In addition, high ECT2 expression can predict adverse clinical outcomes in GC patients. More importantly, ECT2 knockdown weakened the resistance of 5-FU in GC cells. ECT2 silencing reduced the cell migratory and invasive abilities of GC cells treated with 5-FU. We also found that downregulation of ECT2 increased 5-FU sensitivity in GC cells by downregulating P-gp, MRP1, and Bcl-2.
CONCLUSION
Upregulation of ECT2 can predict adverse clinical outcomes and increase 5-FU resistance in GC patients.
背景
已有报道称上皮细胞转化序列2（ECT2）在胃癌（GC）中的异常表达及预后预测情况。然而，ECT2对GC中5-氟尿嘧啶（5-Fu）耐药性的影响尚不清楚。本研究旨在解决上述问题。
方法
通过逆转录定量聚合酶链反应（RT-qPCR）和蛋白质免疫印迹分析检测基因表达。通过集落形成试验、MTT试验和流式细胞术分析评估细胞活力。采用Transwell和伤口愈合试验检测细胞转移情况。
结果
在胃腺癌（STAD）和GC组织中发现ECT2上调。此外，ECT2高表达可预测GC患者的不良临床结局。更重要的是，ECT2敲低减弱了GC细胞对5-FU的耐药性。ECT2沉默降低了用5-FU处理的GC细胞的迁移和侵袭能力。我们还发现，ECT2下调通过下调P-糖蛋白（P-gp）、多药耐药相关蛋白1（MRP1）和Bcl-2增加了GC细胞对5-FU的敏感性。
结论
ECT2上调可预测GC患者的不良临床结局并增加其对5-FU的耐药性。
Zotero 插件